As a result, after the revolutionary data on the metastatic setting of epidermal growth factor receptor (EGFR) inhibitors (9–13), we, nowadays, have the impressive results of the Adaura trial, which led to an important improvement of disease-free survival (DFS) in a subset of patients with EGFR-mutated early-stage lung cancer when osimertinib was added as an adjuvant treatment to the main treatment for the duration of 3 years (14). The gene discussed is EGFR; the disease is lung carcinoma.